In Vivo Pharmacology Services
The use of in vivo experimental models brings us closer to the real human physiological environment, providing valuable data support for clinical trials. Alfa Cytology has a designable animal model of leukemia and has accumulated a wealth of in vivo pharmacology expertise in the field of leukemia treatment. Our extensive experience includes testing a wide range of drugs, such as small molecules, macromolecules, natural products, antibodies, other biological products, and vaccines, to expedite the development of treatments for leukemia.
Introduction to In Vivo Pharmacology
Leukemia is a malignant tumor of the hematological system, and the prognosis of its patients is not ideal. In order to solve this problem, more and more new drugs have been developed, but few drugs can be approved. Pharmacological experiments in vivo can model the complex environment in vivo, evaluate the real therapeutic effect of drugs on leukemia, verify the effectiveness of the new therapy, and provide effective data for follow-up clinical trials.
Fig. 1. In vitro and in vivo anti-leukemia activity of the stem bark of Salacia impressifolia. (Rodrigues, A.C.B.C. et al., 2019)
Selection of Leukemia Model
The choice of a leukemia model determines the success of drug development. We have a variety of leukemia models to choose from. Using these leukemia models, we can well model the absorption and effect of drugs in leukemia, and evaluate the therapeutic effect, mechanism, and side effects of drugs on leukemia.
- Syngeneic mouse models
- Cell line-derived xenograft model
- Transgenic mouse model
- Patient-derived xenotransplant models
- Tailored model development
- Humanized models
In Vivo Pharmacology One-Stop Services
Efficacy Evaluation of drug therapy for leukemia
Drug treatment was given in an animal model, and then the effects of drugs on leukemia load, survival rate, hematological indexes (such as white blood cell count, hemoglobin level, etc.), pathology, and immunohistochemical analysis were evaluated. to evaluate the therapeutic effect of the drug.
Determine Optimal Dosing Regimens Services
Our service aims to identify the optimal dosage regimen tailored to your needs. We strive to achieve favorable outcomes with the minimal effective dose, maximizing therapeutic effects while minimizing the pharmacodynamic factors that contribute to adverse events.
Identify Potential Side Effects Services
By measuring the physiological indexes of leukemia animals after administration, the side effects and toxicity of drugs can be evaluated. We provide in vivo pharmacological services for you to study the effects of drugs on the entire physiological system, including the effects of drugs on specific organs, tissues, or cells and the regulation of physiological functions.
In Vivo DMPK Services
We provide comprehensive drug metabolism and pharmacokinetics (DMPK) assessment, delivering a comprehensive report that includes raw data, computational results, and a summary table with calculated parameters. Our in vivo DMPK services involve administering compounds to leukemia animal models and collecting samples within predetermined time intervals.
Advantages of Our Services
- Rich animal models of leukemia.
- Comply with all regulations.
- To evaluate the efficacy and efficacy of drugs for leukemia.
- Designing your study for success.
- Customized leukemic cell model for in vitro pharmacodynamic experiment.
Alfa Cytology provides a variety of models and drug testing to evaluate the effectiveness of small molecular compounds or macromolecular drugs. Alfa Cytology will work with you to determine the most appropriate in vivo pharmacological solution for your drug discovery plan. Our in-vivo pharmacology solutions enable you to make informed decisions based on related data. Please contact us if you are interested in our services or would like to know more.
Reference
- Rodrigues, A.C.B.C.; et al. In vitro and in vivo anti-leukemia activity of the stem bark of Salacia impressifolia (Miers) AC Smith (Celastraceae). Journal of ethnopharmacology, 2019, 231: 516-524.